Neuroinflammation in Amyotrophic Lateral Sclerosis

Neuroinflammation in Amyotrophic Lateral Sclerosis

> Comprehensive analysis of neuroinflammatory mechanisms in ALS pathogenesis, including microglial activation, T-cell infiltration, astrocyte responses, inflammasome pathways, and emerging therapeutic strategies [[PMID: 25955812]], [[PMID: 17327452]], [[PMID: 32437025]]

Overview

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and typically death within 2-5 years of symptom onset. Approximately 30,000 people in the United States have ALS, with 5,000 new diagnoses annually. While 90-95% of cases are sporadic, 5-10% are familial, with mutations in over 40 genes identified as causative. PMID: 25955812

Among all neurodegenerative diseases, ALS exhibits the most robust and widespread neuroinflammatory response. Activated microglia, astrogliosis, and T-cell infiltration are prominent neuropathological features that correlate directly with disease progression rate and severity. The inflammatory response in ALS is driven by mutant SOD1, TDP-43 pathology, and C9orf72 hexanucleotide repeat expansions, creating a self-perpetuating cycle of immune activation and motor neuron degeneration [1][2]. [[PMID: 33268891]], [[PMID: 29478868]], [[PMID: 31748121]]

Neuroinflammation in Amyotrophic Lateral Sclerosis

> Comprehensive analysis of neuroinflammatory mechanisms in ALS pathogenesis, including microglial activation, T-cell infiltration, astrocyte responses, inflammasome pathways, and emerging therapeutic strategies [[PMID: 25955812]], [[PMID: 17327452]], [[PMID: 32437025]]

Overview

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, paralysis, and typically death within 2-5 years of symptom onset. Approximately 30,000 people in the United States have ALS, with 5,000 new diagnoses annually. While 90-95% of cases are sporadic, 5-10% are familial, with mutations in over 40 genes identified as causative. PMID: 25955812

Among all neurodegenerative diseases, ALS exhibits the most robust and widespread neuroinflammatory response. Activated microglia, astrogliosis, and T-cell infiltration are prominent neuropathological features that correlate directly with disease progression rate and severity. The inflammatory response in ALS is driven by mutant SOD1, TDP-43 pathology, and C9orf72 hexanucleotide repeat expansions, creating a self-perpetuating cycle of immune activation and motor neuron degeneration [1][2]. [[PMID: 33268891]], [[PMID: 29478868]], [[PMID: 31748121]]

The unique feature of neuroinflammation in ALS is its extensive spatial distribution throughout the central nervous system. Unlike other neurodegenerative diseases with regional specificity, ALS shows widespread microglial activation in the motor cortex, brainstem, and spinal cord. This pervasive inflammation reflects the fact that motor neurons are distributed throughout these regions, and the inflammatory response follows the pattern of motor neuron degeneration. [[PMID: 28957377]], [[PMID: 28515465]], [[PMID: 28751247]]

Microglial Activation in ALS

Temporal Dynamics

Microglial activation in ALS begins early in disease pathogenesis, often preceding detectable motor neuron loss. Studies in mutant SOD1 transgenic mice show that microglial activation is detectable by 8 weeks of age, weeks before symptom onset. This early activation suggests that neuroinflammation may contribute to disease initiation rather than simply being a consequence of neuronal death. [[PMID: 30895205]], [[PMID: 32372026]], [[PMID: 34236578]]

The progression of microglial activation follows a predictable pattern:

• Early stage (pre-symptomatic): Limited microglial activation near motor neurons
• Early symptomatic: Widespread activation in spinal cord and motor cortex
• Late stage: Maximal activation throughout the CNS, correlating with rapid disease progression [[PMID: 35035879]], [[PMID: 33171316]], [[PMID: 34298765]]

Microglial Phenotypes in ALS

Microglia in ALS exist in multiple phenotypic states with distinct functions:

Disease-Associated Microglia (DAM):

• Upregulate TREM2, APOE, and ITGAX
• Exhibit phagocytic hyperactivity
• Produce pro-inflammatory cytokines
• Found surrounding motor neurons

• Express anti-inflammatory markers (ARG1, IL-10)
• Promote tissue repair
• Support neuronal survival
• May be therapeutic targets

TREM2 in ALS

TREM2 variants influence ALS risk and progression:

• TREM2 R47H variant associated with altered microglial responses
• TREM2 deficiency in models shows worsened outcomes
• TREM2 activation may be therapeutically beneficial
• Soluble TREM2 as potential biomarker [PMID: 35035879], [PMID: 33171316]

Neuroinflammation and Muscle Function

Peripheral Immune Activation

Neuroinflammation in ALS extends beyond the CNS:

Muscle Inflammation: Inflammatory infiltrates in ALS muscle include macrophages and T-cells. These cells release cytokines that affect muscle fiber function.

Circulating Cytokines: Elevated peripheral cytokines include IL-6, TNF-α, and IL-1β. These systemic inflammatory markers correlate with disease progression.

Neuromuscular Junction

The neuromuscular junction shows inflammatory changes:

Synaptic Stripping: Activated microglia may strip synapses from motor neurons. This process contributes to denervation in ALS.

Schwann Cell Dysfunction: Inflammatory cytokines affect Schwann cell function. These cells support motor neuron terminals and myelin maintenance.

Therapeutic Implications

Anti-Inflammatory Therapies

Multiple anti-inflammatory approaches are being explored:

Minocycline: This antibiotic inhibits microglial activation. Clinical trials in ALS showed modest benefit.

Corticosteroids: These potent anti-inflammatories have been tried in ALS. However, side effects limit long-term use.

NP001: This novel anti-inflammatory compound targets NF-κB signaling. Phase II trials showed slowed progression in a subset of patients.

Immunomodulatory Approaches

Modulating the immune response:

Microglial Modulation: Targeting microglial activation states may shift them toward protective phenotypes. Colony-stimulating factor 1 receptor (CSF1R) antagonists are in development.

T-cell Modulation: Regulatory T-cell function is reduced in ALS. Enhancing Treg function may provide benefit.

Cytokine Blockade: Blocking specific cytokines like IL-6 may reduce neuroinflammation. Tocilizumab, an IL-6 receptor antibody, is being evaluated.

Biomarkers of Neuroinflammation

Fluid Biomarkers

Neuroinflammation produces detectable changes:

CSF Cytokines: Elevated IL-6, TNF-α, and IL-1β in ALS CSF indicate active inflammation.

NfL and炎症 Markers: Neurofilament light chain (NfL) rises with neuronal injury. Combined with inflammatory markers, it provides disease activity information.

Tremor: Soluble TREM2 in CSF reflects microglial activation.

Imaging Biomarkers

Neuroimaging can detect inflammation:

PET TSPO: This ligand binds to activated microglia. TSPO PET shows increased signal in ALS motor cortex.

MR Spectroscopy: Elevated choline indicates membrane turnover from inflammation.

References